- Home
- DXC vs BCRX Comparison
DXC vs BCRX Comparison
Compare DXC & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXC | BCRX |
|---|---|---|
| Founded | 1959 | 1986 |
| Country | United States | United States |
| Employees | 130000 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2016 | 1995 |
Fundamental Metrics
Financial Performance| Metric | DXC | BCRX |
|---|---|---|
| Price | $11.94 | $9.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $15.33 | ★ $20.82 |
| AVG Volume (30 Days) | 2.1M | ★ 5.0M |
| Earning Date | 01-29-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 356.52 | ★ 381.40 |
| EPS | 0.88 | ★ 1.21 |
| Revenue | ★ $12,871,000,000.00 | $25,186,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.55 |
| P/E Ratio | $13.25 | ★ $7.58 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.59 | $6.00 |
| 52 Week High | $17.68 | $11.31 |
Technical Indicators
Market Signals| Indicator | DXC | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 74.99 |
| Support Level | $11.72 | $7.95 |
| Resistance Level | $15.67 | N/A |
| Average True Range (ATR) | 0.47 | 0.43 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 21.58 | 95.07 |
Price Performance
Historical ComparisonAbout DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.